ChinaAMC Hang Seng Biotech ETF (03069.HK) Up 1.86% as Hong Kong Biotech Rallies

NewTimeSpace News: As of 10:22 on November 9, ChinaAMC Hang Seng Biotech ETF (03069.HK) rose 1.86% to a latest price of HK$15.370. The ETF has so far traded 5.8001 million units today, with turnover of HK$89.5672 million and an average price of HK$15.442; its turnover rate is 2.681%. It has gained 1.86% week to date. The net asset value per unit is HK$15.0617, and assets under management stand at HK$3.259 billion. (Note: NAV and AUM are as of November 6; the week-to-date change is based on the previous close of HK$15.090 on November 6, so it matches the one-day gain.)

Hong Kong biotech shares rallied on November 9. The Hang Seng Biotech Index was up 2.67% at 9:41, while the Hang Seng Index gained 0.72% and the Hang Seng TECH Index 1.01% over the same period. Among individual names, as of 10:08, Zai Lab rose 13.07%, Keymed Biosciences 7.22%, Akeso 6.33%, Kelun-Biotech 5.36%, WuXi Biologics 4.96%, GenScript Biotech 4.48% and Henlius Biotech 4.04%. On the news front, China's National Medical Products Administration approved the marketing of pogenlacel injection (brand name Saibohua) developed by Beijing Immunochina Pharmaceuticals, for adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma not otherwise specified, grade 3b follicular lymphoma and high-grade B-cell lymphoma.

ChinaAMC Hang Seng Biotech ETF (03069.HK) is a passive ETF under ChinaAMC (Hong Kong) that closely tracks the Hang Seng Biotech Index. Compiled by Hang Seng Indexes on a net total return basis, the index reflects the performance of the 30 largest Stock Connect-eligible biotech companies listed in Hong Kong, including pre-revenue companies listed under Chapter 18A. Constituents span biotechnology, pharmaceuticals, pharmaceutical distribution, pharmaceutical and biotech contract services, and medical equipment and supplies, weighted by free-float market capitalisation with a 10% cap on any single constituent. The product listed on March 18, 2021, with a management fee of 0.5% per year.

Xiangcai Securities believes that continued demand for pharmaceutical innovation and steady growth in global R&D spending are lifting demand for cutting-edge pipelines and complex molecules, further opening up growth space for the CXO industry. It argues that Chinese innovative drugs have entered a new globalisation phase, achieving technological breakthroughs in frontier areas such as ADCs and bispecifics and moving from follow-on innovation toward original innovation. In the first half of 2026, global biotech financing, licensing deals and M&A transactions reached US$50.2 billion, US$166.7 billion and US$96 billion respectively, all well above the year-earlier period.